08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Mylan deal

Valeant divested generic versions of dermatology drugs BenzaClin clindamycin/benzoyl peroxide gel and Efudex fluorouracil cream to Mylan. The deal includes an ANDA for generic BenzaClin to treat acne and a license to manufacture and...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Sanofi deal

Valeant will acquire Sanofi's Dermik dermatology unit for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had total 2010 revenue of about $240 million. Valeant...
00:18 , Jul 12, 2011 |  BC Extra  |  Company News

Sanofi sells dermatology business to Valeant

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired the Dermik dermatology unit from Sanofi (Euronext:SAN; NYSE:SNY) for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Company News

A.P. Pharma, Paul Capital Partners deal

A.P. Pharma received the final $2.5 million milestone payment from Paul Capital's Paul Royalty Fund under a 2005 deal in which Paul Capital purchased royalty rights to A.P. Pharma's acne drug Retin-A Micro and...
07:00 , Sep 8, 2008 |  BioCentury  |  Regulation

Refinement wanted

Refinement wanted As mandated by the FDA Amendments Act of 2007, FDA last week released its first quarterly report on potential signals of risk for marketed drugs. Under FDAAA, the agency must report new...
07:00 , Jun 11, 2007 |  BC Week In Review  |  Company News

A.P. Pharma, Paul Capital Partners deal

APPA received a $2.5 million milestone payment from Paul Capital's Paul Royalty Fund under a deal in which Paul Capital purchased royalty rights to acne drug Retin-A Micro and actinic keratosis drug Carac...
08:00 , Jan 23, 2006 |  BC Week In Review  |  Company News

A.P. Pharma, J&J, Paul Capital Partners sales and marketing update

A.P. Pharma Inc. (APPA), Redwood City, Calif.   Johnson & Johnson (JNJ), New Brunswick, N.J.   Paul Capital Partners, New York, N.Y.   Business: Dermatology   Paul Capital's Paul Royalty Fund purchased royalty rights to two APPA drugs: ...
08:00 , Feb 28, 2005 |  BC Week In Review  |  Clinical News

Carac 5-fluorouracil dermatology data

Data from a 12-month, placebo-controlled study in 142 patients showed that treatment with 0.5% Carac cream prior to cryosurgery is significantly more effective in reducing AK lesions than placebo plus cryosurgery. After 4 weeks, mean...
07:00 , Apr 16, 2001 |  BC Week In Review  |  Company News

Advanced Polymer sales and marketing update

APOS partner Dermik Laboratories Inc., a subsidiary of Aventis S.A. (AVE, Strasbourg, France), launched APOS's Carac Microsponge formulation of 5-FU to treat actinic keratoses. APOS will receive royalties. Advanced Polymer Systems Inc. (APOS),...